Scale and capacity Delpharm Gaillard is a mid-sized European CDMO with a specialized focus on dry and effervescent pharmaceutical forms and a footprint within a larger manufacturing group, indicating potential for cross-site collaboration, capacity planning, and tiered outsourcing strategies.

Recent expansion The company has a track record of significant investments and facility upgrades across Europe and North America, including new sterile lines and vaccine-related manufacturing, signaling openness to large-scale CDMO projects and multi-site partnerships.

Key partnerships Past collaborations with Pfizer/BioNTech, Sandoz, and BioNTech US, among others, suggest a strong capability in fill-finish, sterile manufacturing, and complex biologics-adjacent programs, presenting opportunities for similar high-complexity projects.

Financial signals Recent financing activity and planned multi-million dollar investments imply strategic growth and potential capacity expansion that could align with customers seeking reliable long-term manufacturing partners and scalable pricing models.

Technology stack Utilization of systems like Sage FRP, AutoCAD, SPIP, and SQL-based tools indicates mature operational processes and data-enabled manufacturing, which can be leveraged to position Delpharm Gaillard for integrated quality, traceability, and digital collaboration with prospective clients.